The question of whether menopausal hormone therapy should be prescribed with longevity as a primary indication — particularly in women over 65 — sits at one of the most contested and consequential intersections in women's health medicine. Observational data and biological plausibility suggest meaningful benefits for cardiovascular health, bone density, cognitive function, and all-cause mortality. Yet randomized trial evidence, timing hypotheses, and risk-benefit calculations in older women remain the subject of genuine expert disagreement. In this inaugural HERmedicine Great Debates in Menopause session, a panel of leading clinicians and researchers takes on the question directly: should MHT be prescribed for life extension and longevity in women over 65?

Panelists will present and defend opposing positions, critically examine the evidence, and engage with the clinical and ethical complexities this question demands. Designed for clinicians ready to move beyond the guidelines and wrestle with the science, this is the debate the field has been having quietly — now out in the open.